Currently, biomarkers such as PD-L1 positivity, microsatellite instability (MSI)/mismatch repair (MMR), EBV, and tumor mutational load (TMB) are used in gastric cancer patients receiving immunotherapy to predict the effectiveness of immunosuppressive drugs (17). Here, CD274 is linked to neoplasm.